151 related articles for article (PubMed ID: 29353057)
1. Mechanisms of Enhanced Osteoclastogenesis in Alkaptonuria.
Brunetti G; Tummolo A; D'Amato G; Gaeta A; Ortolani F; Piacente L; Giordano P; Colucci S; Grano M; Papadia F; Faienza MF
Am J Pathol; 2018 Apr; 188(4):1059-1068. PubMed ID: 29353057
[TBL] [Abstract][Full Text] [Related]
2. Bone impairment in phenylketonuria is characterized by circulating osteoclast precursors and activated T cell increase.
Roato I; Porta F; Mussa A; D'Amico L; Fiore L; Garelli D; Spada M; Ferracini R
PLoS One; 2010 Nov; 5(11):e14167. PubMed ID: 21152388
[TBL] [Abstract][Full Text] [Related]
3. An update on the role of RANKL-RANK/osteoprotegerin and WNT-ß-catenin signaling pathways in pediatric diseases.
Brunetti G; D'Amato G; Chiarito M; Tullo A; Colaianni G; Colucci S; Grano M; Faienza MF
World J Pediatr; 2019 Feb; 15(1):4-11. PubMed ID: 30343446
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-21 promotes osteoclastogenesis in RAW264.7 cells through the PI3K/AKT signaling pathway independently of RANKL.
Xing R; Zhang Y; Li C; Sun L; Yang L; Zhao J; Liu X
Int J Mol Med; 2016 Oct; 38(4):1125-34. PubMed ID: 27599586
[TBL] [Abstract][Full Text] [Related]
5. Receptor activator of nuclear factor kappa B ligand-mediated osteoclastogenesis is elevated in ankylosing spondylitis.
Im CH; Kang EH; Ki JY; Shin DW; Choi HJ; Chang EJ; Lee EY; Lee YJ; Lee EB; Kim HH; Song YW
Clin Exp Rheumatol; 2009; 27(4):620-5. PubMed ID: 19772794
[TBL] [Abstract][Full Text] [Related]
6. Impaired bone remodeling in children with osteogenesis imperfecta treated and untreated with bisphosphonates: the role of DKK1, RANKL, and TNF-α.
Brunetti G; Papadia F; Tummolo A; Fischetto R; Nicastro F; Piacente L; Ventura A; Mori G; Oranger A; Gigante I; Colucci S; Ciccarelli M; Grano M; Cavallo L; Delvecchio M; Faienza MF
Osteoporos Int; 2016 Jul; 27(7):2355-2365. PubMed ID: 26856585
[TBL] [Abstract][Full Text] [Related]
7. Higher levels of s-RANKL and osteoprotegerin in children and adolescents with type 1 diabetes mellitus may indicate increased osteoclast signaling and predisposition to lower bone mass: a multivariate cross-sectional analysis.
Tsentidis C; Gourgiotis D; Kossiva L; Doulgeraki A; Marmarinos A; Galli-Tsinopoulou A; Karavanaki K
Osteoporos Int; 2016 Apr; 27(4):1631-1643. PubMed ID: 26588909
[TBL] [Abstract][Full Text] [Related]
8. Non-Canonical (RANKL-Independent) Pathways of Osteoclast Differentiation and Their Role in Musculoskeletal Diseases.
Sabokbar A; Mahoney DJ; Hemingway F; Athanasou NA
Clin Rev Allergy Immunol; 2016 Aug; 51(1):16-26. PubMed ID: 26578261
[TBL] [Abstract][Full Text] [Related]
9. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
[TBL] [Abstract][Full Text] [Related]
10. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
11. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
[TBL] [Abstract][Full Text] [Related]
12. LIGHT (TNFSF14), a novel mediator of bone resorption, is elevated in rheumatoid arthritis.
Edwards JR; Sun SG; Locklin R; Shipman CM; Adamopoulos IE; Athanasou NA; Sabokbar A
Arthritis Rheum; 2006 May; 54(5):1451-62. PubMed ID: 16649193
[TBL] [Abstract][Full Text] [Related]
13. Osteoclastogenesis in children with 21-hydroxylase deficiency on long-term glucocorticoid therapy: the role of receptor activator of nuclear factor-kappaB ligand/osteoprotegerin imbalance.
Faienza MF; Brunetti G; Colucci S; Piacente L; Ciccarelli M; Giordani L; Del Vecchio GC; D'Amore M; Albanese L; Cavallo L; Grano M
J Clin Endocrinol Metab; 2009 Jul; 94(7):2269-76. PubMed ID: 19401376
[TBL] [Abstract][Full Text] [Related]
14. RANKL:osteoprotegerin ratio and bone mineral density in children with untreated juvenile dermatomyositis.
Rouster-Stevens KA; Langman CB; Price HE; Seshadri R; Shore RM; Abbott K; Pachman LM
Arthritis Rheum; 2007 Mar; 56(3):977-83. PubMed ID: 17328075
[TBL] [Abstract][Full Text] [Related]
15. Daily administration of eldecalcitol (ED-71), an active vitamin D analog, increases bone mineral density by suppressing RANKL expression in mouse trabecular bone.
Harada S; Mizoguchi T; Kobayashi Y; Nakamichi Y; Takeda S; Sakai S; Takahashi F; Saito H; Yasuda H; Udagawa N; Suda T; Takahashi N
J Bone Miner Res; 2012 Feb; 27(2):461-73. PubMed ID: 22052469
[TBL] [Abstract][Full Text] [Related]
16. Investigation of osteoclastogenic signalling of the RANKL substitute LIGHT.
Hemingway F; Kashima TG; Knowles HJ; Athanasou NA
Exp Mol Pathol; 2013 Apr; 94(2):380-5. PubMed ID: 23391709
[TBL] [Abstract][Full Text] [Related]
17. Circulating levels of osteoprotegerin and receptor activator of NF-kappaB ligand in patients with chronic renal failure.
Shaarawy M; Fathy SA; Mehany NL; Hindy OW
Clin Chem Lab Med; 2007; 45(11):1498-503. PubMed ID: 17970704
[TBL] [Abstract][Full Text] [Related]
18. Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB, osteoprotegerin, and receptor activator of nuclear factor kappaB ligand.
Lee CK; Lee EY; Chung SM; Mun SH; Yoo B; Moon HB
Arthritis Rheum; 2004 Dec; 50(12):3831-43. PubMed ID: 15593184
[TBL] [Abstract][Full Text] [Related]
19. Changes in RANKL/OPG/RANK gene expression in peripheral mononuclear cells following treatment with estrogen or raloxifene.
Bashir A; Mak YT; Sankaralingam S; Cheung J; McGowan NW; Grigoriadis AE; Fogelman I; Hampson G
Steroids; 2005 Dec; 70(13):847-55. PubMed ID: 16005483
[TBL] [Abstract][Full Text] [Related]
20. Sanguiin H-6, a constituent of Rubus parvifolius L., inhibits receptor activator of nuclear factor-κB ligand-induced osteoclastogenesis and bone resorption in vitro and prevents tumor necrosis factor-α-induced osteoclast formation in vivo.
Sakai E; Aoki Y; Yoshimatsu M; Nishishita K; Iwatake M; Fukuma Y; Okamoto K; Tanaka T; Tsukuba T
Phytomedicine; 2016 Jul; 23(8):828-37. PubMed ID: 27288918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
